IDEAYA Biosciences has completed targeted full enrollment in its Phase 2/3 OptimUM-02 trial evaluating darovasertib in combination with crizotinib as a first-line treatment for HLA*A2-negative metastatic uveal melanoma. The company aims to support a potential accelerated approval filing in the United States based on median progression-free survival data expected in the first quarter of 2026.

Why the trial’s enrollment milestone reflects a shift in rare ocular oncology strategy

IDEAYA Biosciences has moved closer to a possible regulatory inflection point in metastatic uveal melanoma, a space long defined by limited therapeutic progress and high unmet need. With the completion of enrollment in the pivotal OptimUM-02 study, the U.S.-based precision oncology company is targeting a highly specific patient population—HLAA2-negative metastatic uveal melanoma—where treatment options remain particularly sparse. While existing therapies like tebentafusp are limited to HLAA2-positive patients, IDEAYA’s candidate offers the potential for a broader therapeutic reach.

The randomized design of the trial, which pits the darovasertib and crizotinib combination against current standards such as pembrolizumab, ipilimumab plus nivolumab, and dacarbazine, is notable in this niche indication. Industry analysts point to the dual-arm structure and use of standard-of-care comparators as a sign that IDEAYA is positioning the combination for direct clinical and regulatory comparison, not just exploratory development. The company is pursuing both accelerated and full approval pathways, with progression-free survival acting as the basis for the former and median overall survival as the long-term endpoint for the latter.

What distinguishes darovasertib’s mechanism and rationale from current treatment standards

Darovasertib, an investigational oral protein kinase C inhibitor, is being developed to address molecular pathways that are particularly relevant to the pathogenesis of uveal melanoma. Unlike cutaneous melanoma, which often responds to immune checkpoint inhibitors, metastatic uveal melanoma is characterized by a low mutational burden and immune-cold tumor microenvironment. This has translated into poor response rates for traditional immunotherapy regimens in this population, particularly among patients who lack the HLA*A2 biomarker necessary for response to tebentafusp.

The combination of darovasertib with crizotinib, a c-MET inhibitor developed by Pfizer, is designed to inhibit two critical signaling pathways associated with tumor proliferation and metastasis. The scientific rationale behind this dual blockade targets not only the oncogenic drivers of the disease but also the potential compensatory mechanisms that tumors may activate to resist monotherapy approaches. This strategy may offer improved durability of response and clinical benefit in a cancer subtype where median overall survival typically ranges from six to twelve months.

Why the upcoming PFS data could be a defining moment for IDEAYA Biosciences

IDEAYA Biosciences expects to release median progression-free survival data from the OptimUM-02 trial in the first quarter of 2026. This topline readout will serve as the basis for a potential accelerated approval filing with the U.S. Food and Drug Administration. The stakes are high, given that few therapies have demonstrated sufficient activity in this setting to justify full-scale regulatory filings. The prior Phase 1/2 OptimUM-01 trial provided a promising signal, with a reported median overall survival of 21.1 months and a median PFS of 7.0 months across both HLAA2-positive and HLAA2-negative patients.

If these figures are confirmed or improved upon in the randomized, biomarker-stratified OptimUM-02 trial, IDEAYA could present one of the most compelling cases to date for a targeted therapy in HLA*A2-negative metastatic uveal melanoma. Regulatory experts following the field suggest that a strong PFS signal may be sufficient to justify early market entry, especially if safety data remain consistent with earlier-phase trials and if patient-reported outcomes support the clinical utility of the regimen.

How darovasertib’s regulatory designations strengthen IDEAYA’s lead asset strategy

Darovasertib has already received multiple designations from the U.S. Food and Drug Administration that reflect its potential clinical value. These include Orphan Drug status for both primary and metastatic uveal melanoma, Fast Track designation for the combination with crizotinib, and Breakthrough Therapy designation in the neoadjuvant setting for enucleation-recommended primary uveal melanoma. Collectively, these designations provide mechanisms for expedited review and increased engagement with regulatory authorities.

This regulatory scaffolding positions IDEAYA Biosciences to move rapidly from data readout to potential filing. It also creates optionality for darovasertib across multiple lines of therapy and disease stages. The company is concurrently advancing a Phase 3 trial, OptimUM-10, evaluating single-agent darovasertib in the neoadjuvant setting. This multi-pronged development strategy increases the likelihood that the molecule could anchor a new treatment paradigm across the uveal melanoma continuum.

What hurdles remain before darovasertib can reshape the treatment landscape

Despite its momentum, IDEAYA’s program still faces several open questions. The ultimate magnitude of benefit in the randomized cohort remains to be seen, and survival data, while promising in earlier trials, must hold up under scrutiny in a controlled head-to-head comparison. The narrow biomarker focus also raises challenges related to trial generalizability and commercial scalability. Manufacturing readiness, distribution infrastructure, and pricing strategy are further hurdles that may influence uptake even if approval is granted.

Reimbursement discussions are likely to be complex. Payers may seek risk-sharing agreements or real-world data supplements, especially if darovasertib is granted accelerated approval based on surrogate endpoints. Analysts believe that although IDEAYA is well-positioned to deliver on its regulatory goals, the real test will lie in its ability to build out the post-approval ecosystem necessary for widespread clinical adoption.

Why this program stands out in the broader landscape of ocular oncology

The rarity of metastatic uveal melanoma has historically disincentivized large-scale pharmaceutical investment, leading to a stagnation in innovation. IDEAYA’s focus on precision mechanisms and biomarker-guided stratification marks a departure from this trend. Its commitment to conducting randomized studies, even in small patient populations, is being viewed as a model for future development in rare cancers.

Clinicians and researchers tracking ocular oncology believe that the darovasertib and crizotinib combination, if successful, could not only fill a therapeutic void but also set a precedent for targeted combinations in other genomically defined cancers. The fact that this trial includes both progression-free and overall survival as primary endpoints reinforces its potential regulatory robustness.

What to expect next as the uveal melanoma pipeline evolves

IDEAYA Biosciences is expected to announce its PFS results in early 2026. A favorable outcome could rapidly lead to an accelerated approval application, with overall survival data following later in the year or early 2027. The outcome of OptimUM-02 may also shape competitive dynamics in the space, prompting other developers to revisit combination regimens or explore PKC inhibition in broader settings.

In parallel, the OptimUM-10 trial in primary uveal melanoma is expected to yield early data that could further establish darovasertib’s clinical utility. If both trials succeed, IDEAYA will have established not just a product, but a platform for disease-modifying treatment in a historically refractory indication.

Could IDEAYA Biosciences create the first new standard in HLA*A2-negative metastatic uveal melanoma?

The completion of full enrollment in the OptimUM-02 trial marks more than a logistical milestone. It sets the stage for a potentially transformative readout that could lead to the first targeted, first-line therapy in HLA*A2-negative metastatic uveal melanoma. With regulatory designations in place, a mechanistically justified approach, and prior efficacy data that suggest real potential, IDEAYA Biosciences may be on the verge of delivering a long-awaited shift in ocular oncology.

Yet execution risk remains. The company must now prove that early signals translate into real-world benefit under the scrutiny of randomized data and regulatory standards. If it succeeds, IDEAYA will not just have advanced a promising drug. It will have opened the door to a precision oncology model in one of the most underserved corners of melanoma treatment.

  crizotinib, darovasertib, HLA*A2-negative melanoma, IDEAYA Biosciences, melanoma clinical trials, metastatic uveal melanoma, OptimUM-02